Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy
- 22 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 47 (3), 199-218
- https://doi.org/10.1007/s10928-020-09684-2
Abstract
Currently employed methods for qualifying population physiologically-based pharmacokinetic (Pop-PBPK) model predictions of continuous outcomes (e.g., concentration–time data) fail to account for within-subject correlations and the presence of residual error. In this study, we propose a new method for evaluating Pop-PBPK model predictions that account for such features. The approach focuses on deriving Pop-PBPK-specific normalized prediction distribution errors (NPDE), a metric that is commonly used for population pharmacokinetic model validation. We describe specific methodological steps for computing NPDE for Pop-PBPK models and define three measures for evaluating model performance: mean of NPDE, goodness-of-fit plots, and the magnitude of residual error. Utility of the proposed evaluation approach was demonstrated using two simulation-based study designs (positive and negative control studies) as well as pharmacokinetic data from a real-world clinical trial. For the positive-control simulation study, where observations and model simulations were generated under the same Pop-PBPK model, the NPDE-based approach denoted a congruency between model predictions and observed data (mean of NPDE = − 0.01). In contrast, for the negative-control simulation study, where model simulations and observed data were generated under different Pop-PBPK models, the NPDE-based method asserted that model simulations and observed data were incongruent (mean of NPDE = − 0.29). When employed to evaluate a previously developed clindamycin PBPK model against prospectively collected plasma concentration data from 29 children, the NPDE-based method qualified the model predictions as successful (mean of NPDE = 0). However, when pediatric subpopulations (e.g., infants) were evaluated, the approach revealed potential biases that should be explored.Keywords
Funding Information
- National Institutes of Health (1R01-HD076676-01A1)
This publication has 33 references indexed in Scilit:
- Pitfalls of using numerical predictive checks for population physiologically-based pharmacokinetic model evaluationJournal of Pharmacokinetics and Pharmacodynamics, 2019
- Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration’s Office of Clinical PharmacologyJournal of Pharmaceutical Sciences, 2019
- Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case StudyCPT: Pharmacometrics & Systems Pharmacology, 2017
- Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic DataClinical Pharmacokinetics, 2017
- Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 TransporterCPT: Pharmacometrics & Systems Pharmacology, 2016
- Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in ChildrenCPT: Pharmacometrics & Systems Pharmacology, 2016
- Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adultsCancer Chemotherapy and Pharmacology, 2013
- A Workflow Example of PBPK Modeling to Support Pediatric Research and Development: Case Study with LorazepamThe AAPS Journal, 2013
- Innovative clinical trial design for pediatric therapeuticsExpert Review of Clinical Pharmacology, 2011
- Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of DrugsJournal of Pharmacokinetics and Pharmacodynamics, 2007